Thus, for all patients with a history of a PCC, follow-up for at least 10 years is suggested [39,42]; for high-risk PCC patients (germline mutation, young age <20 years, large tumor ≥5–6 cm, for SDHB carriers tumor size ≥3–3.5 cm) and all PGL patients lifelong surveillance is recommended—at least consisting of a yearly clinical investigation and assessment of urinary or plasma metanephrines and 3-methoxytyramine (see above) [39,42,88]. Here, SDHB is linked to neoplasm.